8-K: Coya Therapeutics Secures $11.1M Private Placement

Coya Therapeutics announced an $11.1 million private placement led by Dr. Reddys Laboratories and Greenlight Capital to fund commercial readiness for COYA 302.

Summary

• Coya Therapeutics, Inc. entered into a Securities Purchase Agreement on January 29, 2026, for a private placement of 2,522,727 shares of its common stock at a purchase price of $4.40 per share.
• The offering is expected to generate gross proceeds of approximately $11.1 million before deducting offering expenses.
• Key investors include Dr. Reddys Laboratories, Inc., a subsidiary of a current strategic collaborator, with a $10.0 million investment, and Greenlight Capital, an existing institutional stockholder, with a $1.1 million investment.
• The net proceeds will be used to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 (LD IL-2) to support the commercial readiness of COYA 302.
• The company reiterates its cash runway guidance into the second half of 2027, extending past the projected topline for the ALSTARS trial.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, as the capital raise strengthens the company's financial position, accelerates a key product's commercial readiness, and is supported by a strategic partner, all while maintaining cash runway guidance.

Positives

• Secured $11.1 million in gross proceeds, significantly strengthening the company's financial position.
• A substantial $10.0 million investment from Dr. Reddys Laboratories, Inc., a subsidiary of a current strategic collaborator, signals strong partnership and confidence in COYA 302.
• The funding will accelerate critical manufacturing and commercial readiness efforts for COYA 302, a key investigational product for neurodegenerative disorders.
• Cash runway guidance is reiterated into the second half of 2027, extending past the projected topline for the ALSTARS trial, providing financial stability for ongoing development.

Negatives

• The issuance of 2,522,727 shares of common stock will result in dilution for existing shareholders.

Risks

• Market conditions and the satisfaction of customary closing conditions related to the offering.
• Risks associated with the success, cost, and timing of product candidate development activities and ongoing and planned clinical trials.
• Uncertainty regarding the ability of product candidates to achieve applicable endpoints in clinical trials.
• Exploratory clinical signals may not be predictive of outcomes in larger, randomized controlled trials.
• The safety profile of product candidates.
• The potential for data from clinical trials to support a marketing application, as well as the timing of these events.
• The ability to obtain funding for operations, development, and commercialization of product candidates.
• The timing of and the ability to obtain and maintain regulatory approvals.
• The rate and degree of market acceptance and clinical utility of product candidates.
• The size and growth potential of the markets for product candidates, and the ability to serve those markets.
• Commercialization, marketing, and manufacturing capabilities and strategy.
• Future agreements with third parties in connection with the commercialization of product candidates.
• Expectations regarding the ability to obtain and maintain intellectual property protection.
• Dependence on third-party manufacturers.
• The success of competing therapies or products that are or may become available.
• The ability to attract and retain key scientific or management personnel.
• The ability to identify additional product candidates with significant commercial potential consistent with commercial objectives.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.

Future Outlook

The company expects the proceeds from the offering to fund its now accelerated commercial readiness plans for COYA 302 with no impact to its cash runway guidance, which is reiterated into the second half of 2027 and past the projected topline for the ALSTARS trial.

Management Comments

• "The Company intends to use the net proceeds from the Offering in order to tech transfer low dose IL-2 (LD IL-2) to an appropriate manufacturing facility, scale up manufacturing capabilities of LD IL-2 and accelerate manufacturing programs, in all cases, as necessary to support commercial readiness of COYA 302."
• "The Company expects the proceeds from the Offering to allow it to fund its now accelerated commercial readiness plans with no impact to its cash runway guidance."
• "The Company reiterates its cash runway guidance into the second half of 2027 and past the projected topline for ALSTARS trial."

Industry Context

StockSavvy.ai notes that securing $11.1 million, particularly with a significant investment from a strategic collaborator like Dr. Reddys Laboratories, Inc., is a strong indicator of confidence in Coya Therapeutics' COYA 302 program for neurodegenerative disorders. This funding allows the company to accelerate critical manufacturing and commercialization efforts, which is crucial in the highly competitive and capital-intensive biotechnology sector, especially for therapies targeting complex diseases like ALS.

Related Party Transactions

• Greenlight Capital, an existing institutional stockholder of the Company, participated in the private placement with a $1.1 million investment.
• Dr. Reddys Laboratories, Inc., a subsidiary of Coya's current strategic collaborator, made a $10.0 million investment.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares but benefit from strengthened financial position, accelerated product development, and extended cash runway.
• Employees: Benefit from continued funding for operations and accelerated development programs, potentially ensuring job security and progress on key projects.
• Customers/Patients: Potential for accelerated availability of COYA 302 for neurodegenerative disorders like ALS due to enhanced manufacturing and commercial readiness.
• Creditors: Improved financial stability and extended cash runway reduce immediate credit risk.

Next Steps

• Closing of the private placement offering on or about January 30, 2026.
• Filing of a registration statement with the SEC for the resale of the securities no later than 45 days after closing.
• Having the registration statement declared effective by the SEC as promptly as possible, but no later than 75 days after closing.
• Continued development of COYA 302, including the ongoing ALSTARS Trial.

Key Dates

Recommendation

The successful $11.1 million private placement, particularly with strong backing from a strategic collaborator and an existing institutional investor, significantly de-risks Coya Therapeutics' near-term funding needs and accelerates the commercial readiness of COYA 302. The reiteration of cash runway guidance into H2 2027, past a key trial milestone, provides a clear financial horizon. While the equity raise causes dilution, the strategic nature of the investment and the operational acceleration are strong positives. Investors should 'hold' to monitor the progress of COYA 302's development and commercialization efforts, as well as the ALSTARS trial results, which are key catalysts for future valuation.

Keywords

Coya Therapeutics, COYA, Private Placement, Equity Raise, Biotechnology, Neurodegenerative Disorders, ALS, COYA 302, LD IL-2, Dr. Reddys Laboratories, Greenlight Capital, Cash Runway, Clinical Stage, SEC Filing, Form 8-K